Navigation Links
Cybrexa Therapeutics Secures $6 Million in Series B Financing
Date:6/15/2017

Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has secured a Series B round of financing in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, Connecticut Innovations, and a group of private investors participated in the round.

The Series B funding will enable Cybrexa to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).

Cybrexa was founded by successful entrepreneurs Per Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine. Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.

Hellsund commented, “We are very pleased to have closed our Series B financing. Our approach has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of TSDs can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.”

About Cybrexa:
Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. The Company is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led a number of companies from start up to liquidity events.

For more information about Cybrexa, please call 203-717-2731 or visit us on the web at http://www.cybrexa.com

Read the full story at http://www.prweb.com/releases/2017/06/prweb14424114.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Novira Therapeutics Completes $25 Million Series A Financing
3. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
4. Aratana Therapeutics Adds To Drug Development Team
5. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
8. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/13/2018)... ... November 13, 2018 , ... ... Research Water Life Science® in Grants Pass, Oregon believes in the power of ... Aqua® Research Water Life Science® sponsors the Power of Water® on talk radio ...
(Date:11/9/2018)... ... November 08, 2018 , ... IC System, one of the ... to increasing recovery rates by creating a comprehensive contact strategy for each consumer. ... by NLP Logix, a Jacksonville, Florida-based AI solutions company, and leveraged the decades ...
(Date:11/7/2018)... , ... November 07, 2018 , ... Diversified Technologies, ... algae at AzCATI, the Arizona Center for Algae Technology and Innovation at ASU. Funded ... development and trials for those involved with algal and predator control applications. , Algae ...
(Date:11/5/2018)... ... 2018 , ... USARAD Holdings Inc., the leading US Joint ... VC firms announces at Distributed Health 2018 conference November 5-6 (Nashville, TN) implementation ... obtaining its first radiology interpretations, one of the first known true use of ...
Breaking Biology Technology:
(Date:11/20/2018)... ... November 19, 2018 , ... CRISPR | Cas9 Market ... human clinical therapeutics, and animal and disease model), by Products (editing tools, cell ... screening, and agriculture and industrial use), by Patent Activities (patent categories and classification, ...
(Date:11/20/2018)... ... November 20, 2018 , ... Thanks to its long-standing expertise in ID ... ID reader market, as the company now proposes a full range of readers able ... ID reader range can be used by professionals either in a fixed location or ...
(Date:11/20/2018)... ... ... Like many large breed dogs, Jack, a Great Pyrenees, began showing symptoms of ... Rebecca, noticed he was slow to get up and knew something was not quite ... Jack had bilateral hip dysplasia, a congenital condition affecting the formation of the hip ...
Breaking Biology News(10 mins):